News

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A cohort analysis shows state Medicaid programs could assure young children with sickle cell disease receive cost-efficient and critical care in a timely fashion.

A laboratory-based assessment shows children aged 18 - 32 months old were less likely to listen to attention prompts or their parent's requests when provided an iPad versus a standard toy.

Data from an Italy cohort show wheezing episodes decreased by more than 40% among children born during the COVID-19 lockdown period versus a pre-pandemic cohort.

Shreya Doshi, MBBS, FAAP, joined us to discuss some easy opportunities to reduce emissions in your practice and help improve health care sustainability.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

Details of newly FDA-approved roflumilast cream 0.15% for AD in pediatric patients, plus insight and commentary from Lawrence Eichenfield, MD.

An intentional launch date for ustekinumab-ttwe in the United States is set for sometime in February 2025.

The decision target action date was July 7, 2024. At this time, there is no indication from the federal agency to extend the date further.

Annie Certo, MA, and AJ Harris, MS, break down what a “summer slump” is and how it can affect children during summer break from school. The duo offers suggestions on how to combat the negative associations of a “summer slump.”

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

"Parents still ask about this. Indeed, many years ago the FDA approved a prescription form of a PUFA, Vayarin, for the treatment of patients with ADHD. It is no longer available, so I assume it did not work. There may be good reasons for taking a PUFA supplement, but having ADHD is not one of them." -Jon Matthew Farber, MD

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

Matthew M. Davis, MD, MAAP, breaks down a newly-published study highlighting a potential association between COVID-19 vaccination and prevalence of symptomatic childhood asthma.

A discussion evaluating how social media can impact an individual's mental health, and what specific elements of social media could be causing it.

FDA decisions for the 2 accepted NDAs have target action dates of December 29 and December 30, 2024, respectively.

The submission to the FDA includes data from the phase 2b ReNeu trial of patients aged 2 years and older with NF1-associated PN causing significant morbidity.

"Obesity and treatment with growth hormone in children with PWS are known risk factors for hypoventilation as well as OSAS."- Jon Matthew Farber, MD

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The primary endpoint of the study was to measure childhood stigma related to disease visibility.

New data for FDA-approved dupilumab (Dupixent; Regeneron and Sanofi) highlights positive study results for the eosinophilic esophagitis (EoE) treatment in children aged 1 to 11 years.

A retracted paper that erroneously claimed the measles, mumps and rubella (MMR) vaccine caused autism has repercussions still being felt today around topics such as vaccination, misinformation and disinformation, and measles incidence rates.

Shreya Doshi, MBBS, FAAP, explains what health care sustainability is and how the industry contributes to climate change.

"I suspect that some doctors still have not changed their ways, so if you see your ENT, EM, or pediatric colleagues prescribing them, please ask them to stop." - Jon Matthew Farber, MD.

"This decision will have serious health consequences for children and young people," stated the president of the American Academy of Pediatrics.

How providers can advocate for increased research determining social media and its association with youth mental health.

The first thought that emerges is: how can we, as strong and persistent advocates for children and health equity, effectively remove barriers for accessing care that is driven by a dependency on financial resources?

Investigators therefore concluded that ROAR provides an excellent way to identify children at highest risk of having poor reading skills.

The decision makes pitolisant the first and only FDA-approved, non-scheduled treatment option for daytime sleepiness in this patient population.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.